Breaking News Instant updates and real-time market news.

CRBP

Corbus Pharmaceuticals

$6.88

-0.62 (-8.27%)

11:29
10/02/18
10/02
11:29
10/02/18
11:29

Corbus Pharmaceuticals granted U.S. patent related to cannabis

Corbus Pharmaceuticals was granted a U.S. patent for ultrapure tetrahydrocannabinol-11-oic acid synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis, according to a post to the USPTO site that has been passed among traders. Tetrahydrocannabinol, otherwise known as THC, is the active chemical in cannabis. Reference Link

  • 02

    Oct

CRBP Corbus Pharmaceuticals
$6.88

-0.62 (-8.27%)

03/13/18
CANT
03/13/18
NO CHANGE
Target $32
CANT
Overweight
Corbus Pharmaceuticals price target raised to $32 from $28 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros last night raised his price target for Corbus Pharmaceuticals to $32 following the company's Q4 results. The analyst did not find any surprises in the release and remain focused on the company's milestones in 2018. He sees 2018 as a year for execution and keeps an Overweight rating on Corbus.
05/11/18
CANT
05/11/18
NO CHANGE
Target $32
CANT
Overweight
Corbus Pharmaceuticals current valuation attractive, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Corbus Pharmaceuticals with a $32 price target following the company's Q1 results. The analyst views 2018 as a "big year for execution" with the initiation of the Phase 3 RESOLVE-1 study in systemic sclerosis, initiation of the Phase 2b study in cystic fibrosis, and initiation of the Phase 2 study in systemic lupus erythematosus. He finds the stock's current valuation attractive.
09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
09/20/18
JMPS
09/20/18
NO CHANGE
Target $27
JMPS
Outperform
Corbus deal for endocannabinoid compounds makes sense, says JMP Securities
JMP Securities analyst Liisa Bayko said she is pleased with Corbus' announcement that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin. While she thinks the deal "makes a lot of strategic sense," Bayko is not yet incorporating the drug candidates into her valuation given the early stage of these assets. Bayko, who said the new assets represent potential upside, keeps an Outperform rating and $27 price target on Corbus shares.

TODAY'S FREE FLY STORIES

BLK

BlackRock

$417.04

16.81 (4.20%)

11:34
01/16/19
01/16
11:34
01/16/19
11:34
Periodicals
Fake annual letter from BlackRock CEO sent to media outlets, Barron's says »

An email was sent to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

PPG

PPG

$102.31

1.31 (1.30%)

11:30
01/16/19
01/16
11:30
01/16/19
11:30
Options
PPG Industries puts active ahead of earnings »

PPG Industries puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EADSY

Airbus

$0.00

(0.00%)

11:29
01/16/19
01/16
11:29
01/16/19
11:29
Periodicals
Airbus investing $300M for new A220 plant in Alabama, Reuters reports »

Airbus is investing $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$70.49

-2.04 (-2.81%)

, ACN

Accenture

$148.37

1.53 (1.04%)

11:29
01/16/19
01/16
11:29
01/16/19
11:29
On The Fly
Downgrades of IT Hardware sector, AB Inbev among today's top analyst calls »

Check out today's top…

BUD

AB InBev

$70.49

-2.04 (-2.81%)

ACN

Accenture

$148.37

1.53 (1.04%)

HPE

HP Enterprise

$14.08

-0.37 (-2.56%)

NTAP

NetApp

$61.25

-1.23 (-1.97%)

NTNX

Nutanix

$49.83

1.075 (2.20%)

TDC

Teradata

$43.09

1.35 (3.23%)

AAPL

Apple

$155.13

2.09 (1.37%)

AVGO

Broadcom

$255.49

-1.02 (-0.40%)

CRUS

Cirrus Logic

$36.22

0.74 (2.09%)

QRVO

Qorvo

$61.91

0.36 (0.58%)

SWKS

Skyworks

$69.44

0.99 (1.45%)

SYNA

Synaptics

$39.79

0.15 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 30

    Jan

  • 05

    Feb

  • 07

    Feb

  • 12

    Feb

  • 13

    Feb

  • 25

    Feb

RHT

Red Hat

$175.73

0.16 (0.09%)

, IBM

IBM

$121.35

-0.4 (-0.33%)

11:29
01/16/19
01/16
11:29
01/16/19
11:29
Hot Stocks
Red Hat shareholders approve merger with IBM »

In a regulatory filing,…

RHT

Red Hat

$175.73

0.16 (0.09%)

IBM

IBM

$121.35

-0.4 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

BB

BlackBerry

$7.67

0.14 (1.86%)

11:25
01/16/19
01/16
11:25
01/16/19
11:25
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
01/16/19
01/16
11:25
01/16/19
11:25
General news
Atlanta Fed's Q4 GDPNow estimate was stuck at 2.8% »

Atlanta Fed's Q4…

11:25
01/16/19
01/16
11:25
01/16/19
11:25
Conference/Events
UBS communications/media analysts to hold a luncheon meeting »

Communications &…

BLK

BlackRock

$416.74

16.51 (4.13%)

11:23
01/16/19
01/16
11:23
01/16/19
11:23
Hot Stocks
BlackRock says Fink letter 'coming soon' after fake version circulated »

BlackRock's official…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/16/19
01/16
11:17
01/16/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/16/19
01/16
11:16
01/16/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CF

CF Industries

$42.03

-1.26 (-2.91%)

11:15
01/16/19
01/16
11:15
01/16/19
11:15
Options
CF Industries put volume heavy and directionally bearish »

Bearish flow noted in CF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

11:15
01/16/19
01/16
11:15
01/16/19
11:15
General news
U.S. VIX equity volatility rose 1.8% to probe 19.0 »

U.S. VIX equity…

SIG

Signet Jewelers

$33.76

-0.05 (-0.15%)

11:14
01/16/19
01/16
11:14
01/16/19
11:14
Hot Stocks
Signet Jewelers says to pay total of $11M to CFPB, NYS in investigations »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWLO

Twilio

$98.39

-2.03 (-2.02%)

11:13
01/16/19
01/16
11:13
01/16/19
11:13
Rumors
Rumor moving shares of Twilio »

Rumor: Twilio moves off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 12

    Feb

11:10
01/16/19
01/16
11:10
01/16/19
11:10
General news
Treasury Action: curve steepening has been the general trend this year »

Treasury Action: curve…

SQ

Square

$66.03

0.13 (0.20%)

, FISV

Fiserv

$70.17

-4.84 (-6.45%)

11:09
01/16/19
01/16
11:09
01/16/19
11:09
Recommendations
Square, Fiserv, First Data analyst commentary  »

Fiserv deal for First…

SQ

Square

$66.03

0.13 (0.20%)

FISV

Fiserv

$70.17

-4.84 (-6.45%)

FDC

First Data

$20.72

3.17 (18.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

11:05
01/16/19
01/16
11:05
01/16/19
11:05
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

YELP

Yelp

$35.64

0.67 (1.92%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Breaking Hot Stocks news story on Yelp »

Yelp says to review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$35.65

0.68 (1.94%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Breaking Hot Stocks news story on Yelp »

Yelp says 'willing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$35.65

0.68 (1.94%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Yelp says 'open to hearing ideas and investor input, including from SQN' »

Yelp issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$43.85

-3.41 (-7.22%)

11:02
01/16/19
01/16
11:02
01/16/19
11:02
Downgrade
Nordstrom rating change  »

Nordstrom downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KEYS

Keysight Technologies

$68.05

-0.47 (-0.69%)

11:01
01/16/19
01/16
11:01
01/16/19
11:01
Hot Stocks
Keysight Technologies, others sign agreement with UNISOC »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDSI

BioDelivery Sciences

$4.24

0.08 (1.92%)

11:00
01/16/19
01/16
11:00
01/16/19
11:00
Options
Call buyer in BioDelivery Sciences International as the rally continues »

Call buyer in BioDelivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
01/16/19
01/16
11:00
01/16/19
11:00
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.